V-Mail Address Notification, W. N. (William Neill) Bogan, Jr. to His Mother, Catherine F. Bogan, Catherine F. Bogan, November 26, 1944

This V-Mail address form advises Catherine F. Bogan how to address any mail sent to her son, William N. Bogan, Jr. The War And Navy Departments V--Mail Service envelope is postmarked U. S. Postal Service No. 3, November 26, 1944.https://scholarsjunction.msstate.edu/mss-bogan-correspondence/1178/thumbnail.jp

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Carta de R.P. Thacker (U.S. Navy) a Ferran Sunyer , 2 maig 1962

Carta de R.P. Thacker (US Navy), per informar-lo que el comandant W.B. Heidt no podrà anar-lo a visitar el 14 de maig tal com estava previst, perquè encara no està del tot recuperat de l'operació i de la malalti

Carta de John E. Weland (U.S. Navy) a Ferran Sunyer , 20 gener 1964

Carta de John E. Weland (US Navy), per agrair-li l'enviament de sis còpies de la proposta d'investigació "Properties of the Space of the Entire Functions of Infinite Order", i dir-li que ja l'han enviada a Washington perquè la revisin i l'avaluïn

Carta de R.P. Thacker (U.S. Navy) a Ferran Sunyer , 9 abril 1962

Carta de R.P. Thacker (US Navy), per dir que ha rebut el tercer informe quadrimestral del contracte N62558-3079 i les quatre còpies de la factura corresponent al període 1 de gener - 31 de març de 1962

Carta de Thomas L. Saaty (U.S. Navy) a Ferran Sunyer , 23 setembre 1961

Carta de Thomas L. Saaty, cap de la branca de Matemàtiques de l'Office of Naval Research (ONR) de l'US Navy, on diu que la seva proposta del 20 d'abril de 1961 titulada "Exponential Approximations of Functions" ha estat aprovada per l'ONR

Carta de John E. Raymond (U.S. Navy) a Ferran Sunyer , 8 gener 1965

Carta de John E. Raymond (US Navy), on diu que han rebut una còpia del segon informe de progrés (període 1 de octubre - 31 de desembre de 1964), juntament amb la factura corresponent al mateix període, que s'ha enviat al Disbursing Officer